Fig. 2From: Circulating miR-200a is a novel molecular biomarker for early-stage renal cell carcinomaThe receiver operating characteristic curve (ROC) analysis for the discriminative ability between RCC patients and normal controls by the serum miR-200a. a-c ROC curves for the serum miR-200a to differentiation RCC patients from normal controls in the training phase (a), in the validation phase (b), and in the combined two phases (c). d-f ROC curves for the serum miR-200a to discern stage I RCC cases (d), stage II RCC cases (e), and stage I–II RCC cases from controls in the training and validation sets (f)Back to article page